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This report considers whether research involving the creation of human-animal interspecies somatic cell
nuclear transfer (iSCNT) embryos raises new ethical issues, and if so, whether it requires additional or special
criteria and oversight distinct from research on human-animal chimeras.Introduction
This report was undertaken to clarify the ethical issues in human-
animal interspecies somatic cell nuclear transfer (iSCNT)
research and to determine if there are justifiable arguments for
proceeding and, if so, under what constraints. While there is
some overlap with a report on the ethical standards for human-
animal chimera experiments published previously by the ISSCR
Ethics and Public Policy Committee (Hyun et al., 2007a)—here-
after the Chimera Report—we note that the creation of iSCNT
embryos (also known as cytoplasmic hybrid embryos or ‘‘cy-
brids’’) may raise additional ethical issues from those associated
with chimeras. As the creation of both iSCNT embryos and
chimeras for research purposes involves mixing human and
nonhuman animal materials, the ethical foundations appear the
same. However, as the ultimate methods are different and result
in different entities, then one may reasonably ask whether the
moral landscape is different as well. For this reason, in the light
of the further scientific development and of recent public educa-
tion/consultation efforts (HFEA, 2007), we present this follow-up
report. We confine this report primarily to any additional and
special issues worthy of distinct discussion. We begin with defi-
nitions and then proceed to a review of the arguments for and
against the research.
The chimeric organism contains cells originating from more
than one zygote. The Chimera Report was limited to biological
entities formed by transferring multipotent or pluripotent human
stem cells and their derivatives into animals in embryonic, fetal,
and postnatal stages. In contrast, we refer here to human-animal
iSCNT, where embryos are formed by transferring the nucleus of
a human cell into an enucleated animal oocyte for the purpose of
research, in particular, to produce human embryonic stem cells
(hESCs) and to studynuclear reprogramming. In political debates,
the term ‘‘hybrid’’ is sometimes used in the word’s broadest
sense—something heterogeneous in origin or composition—to
describe the iSCNT embryo, as the resultant embryo includes
genetic material from more than one species in the same cell.
The iSCNT embryo contains human nuclear DNA, animal mito-
chondrial DNA (contained in the oocyte’s cytoplasm), and traces
of human mitochondrial DNA (transferred with the nucleus). The
goal of the nuclear transfer is to reprogram the human somatic
DNA to an embryonic state. If the resultant embryo develops to
the blastocyst stage, a line of hESCs might then be derived from
the innercellmass; thisprocesswoulddestroy the iSCNTembryo.
Scientific Justification
For the reasons stated in the Chimera Report, a necessary
precondition for any such research to be justifiable is that the
research:(a) has scientific merit;
(b) has social or humanitarian importance;
(c) has no reasonable, alternative means of answering the
specific research question without the use of the
proposed technology;
(d) satisfies animal research and welfare requirements; and
(e) meets standards of human subjects and stem cell
research oversight review as appropriate; in particular, it
is approved by qualified reviewers who take into consid-
eration the special issues associated with the creation
of research embryos and chimeric animals.
At the outset, it is therefore important to consider whether
iSCNT research is scientifically justified.
A core argument in support of the research can be made in the
classic consequentialist sense that medical research strives to
produce beneficial outcomes and in the deontological premise
that we have a duty to try to relieve human suffering with medical
advances. New avenues of human stem cell research have the
potential to enhance the understanding of serious diseases
and ultimately the development of new ways to treat them.
Through iSCNT, scientistsmaybeable to create andstudy new
hESC lines, including those that carry mutations for human
diseases, and to compare iSCNT lines to stem cell lines derived
through other methods, such as direct reprogramming and
human-human SCNT (hSCNT). The practical and ethical consid-
erations inobtaining unfertilizedhumaneggshavebeencentral to
recent interest in exploiting iSCNTas acomplementary approach
to hSCNT to create patient- or disease-specific ESC lines and in
other avenues of research. Thus, in addition to providing new
hESCs for research, iSCNT research may enable scientists to
observe the development of early embryonic cells. This may
assist understanding of some fundamental questions of stem
cell biology, such as stem cell migration, development, and char-
acterization. Furthermore, iSCNT research may also be useful in
understanding the function of mitochondria in various diseases
and conditions. Finally, knowledge from iSCNT research could
be applied to efforts to protect endangered species or to recover
animals that have become extinct (Beyhan et al., 2007).
While it is hoped that iSCNT embryos could become a source
for deriving new hESC lines, there is scientific debate over
whether iSCNT embryos will actually produce normal human
stem cells. The biggest challenge facing iSCNT research is that
the original experiment in which hESCswere derived using rabbit
oocytes (Chen et al., 2003) has not been repeated. To date, there
are no reports of human stem cell lines derived using any type of
animal eggs. The difficulties are manifest. Genetic divergence
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mitochondria leads to metabolic disruptions. A recent report
demonstrates that bovine and rabbit oocytes did not fully repro-
gram the donor (human) genome (Chung et al., 2009). As a result
of such difficulties, iSCNT embryos do not seem to develop
properly and have not yet survived long enough for stem cell
cultivation, calling into question the potential use of animal
eggs to generate human patient-specific stem cells. However,
most scientists agree that the only way to settle the debate about
whether these embryos will produce viable and useful stem cells
is to continue conducting the research, perhaps by using
different animal eggs and timing nuclear transfer so that genome
activations are synchronized (Fulka et al., 2008; St John and
Lovell-Badge, 2007; Academy of Medical Sciences, 2007).
Hence, it is possible that iSCNT may inform researchers’ under-
standings of SCNT technology and processes, assisting in later
research using SCNT embryos formed from donated human
eggs.
Complementary Steps Forward
Given this array of potential options and the difficulties encoun-
tered so far by research on iSCNT embryos, it is important to
situate this line of inquiry into the broader context of nuclear
reprogramming research and the exploitation of reprogramming
techniques to obtain patient- or disease-tailored pluripotent
stem cell lines. Gene-based reprogramming of adult human
skin fibroblasts into pluripotent stem cells, referred to as induced
pluripotent stem cells (iPSCs), that share many characteristics
with hESCs (Takahashi et al., 2007; Yu et al., 2007; Park et al.,
2008) has clearly changed the practice of this research field
and has placed the regenerative perspectives of human pluripo-
tent stem cells on an altogether more solid footing. By far the
most important feature of iPSC technology is the fact that it is
remarkably simple, enabling many laboratories worldwide to
develop it further. This is in sharp contrast with the field of hSCNT
and also iSCNT, in which the dedicated set of specialized skills
and resources needed prevented many laboratories from
entering the arena and hence contributing to the success of
the field.
Yet, despite these considerations, the very differences
between iPSC and SCNT (including iSCNT) technologies indi-
cate that, at least for the foreseeable future, the advent of the
former does not render the latter obsolete or redundant, but
rather complementary. Starting from the needs of basic research
and proceeding to the clinical applications, the reasons for
continuing iSCNT research are the following.
First, in terms of basic biology, the epigenetic reprogramming
entailed in iPSC versus iSCNT experiments is completely
different (Gurdon and Melton, 2008). In the former, the forced
expression of variable combinations of transcription factors
changes one differentiated cell type (such as adult skin fibro-
blasts) into a pluripotent cell type (iPSCs) that shares many
characteristics with ESCs derived from the inner cell mass of
a blastocyst stage embryo. The process takes weeks and, in
‘‘leaping’’ from a differentiated cell type to another defined, albeit
pluripotent, cell type, does not recapitulate the initial phases of
embryonic development. In SCNT, the oocyte reprograms the
somatic cell nucleus within hours and coaxes it into a reenact-
ment of the developmental stages that follow fertilization. Hence,28 Cell Stem Cell 5, 27–30, July 2, 2009 ª2009 ISSCRif one is interested in understanding the basic biology of oocyte-
driven reprogramming on human somatic cell nuclei, it is clear
that iPSCs cannot substitute for SCNT. And given the problems
associated with the procurement of human eggs, iSCNT, if
successful, would constitute an alternative way to investigate
this issue. Of course, one could ask how much in iSCNT the
admittedly artificial combination of reagents could illuminate
the genuine potential of human oocyte-mediated reprogram-
ming. This is a fundamental concern, but one that can only be
addressed by performing a thorough comparison between
pluripotent cell lines derived by hSCNT versus iSCNT. It is also
possible that recent developments yield a less limited supply
of in vitro-generated human oocytes, such as functional oocytes
produced from hESC or iPSC lines, that would bypass the diffi-
culties associated with animal eggs. Furthermore, if human
zygotes could be used for reprogramming somatic nuclei, in
analogy to what was recently demonstrated in mice (Egli et al.,
2007), the number of supernumerary IVF embryos worldwide
could constitute an important resource.
Second, by recapitulating the early steps of human embryo-
genesis, iSCNT opens an opportunity for the investigation of its
physiological mechanisms and pathological aberrations. This is
an area of significant medical need that, again, is not simply
amenable to research given the scarcity of human eggs. Also
in this case the objection as to the relevance of iSCNT to the
physiology of human postzygotic development is warranted,
but it is again an objection that can only be solved through addi-
tional research. Finally, also concerning this aspect, it is possible
that the in vitro derivation of gametes from ESCs or iPSCs, and
the ability to combine them for large-scale genetic screens of
early in vitro development, would outpace the potential of iSCNT.
When and if these developmentsmaterialize, it will then be useful
to reappraise the scientific rationale for iSCNT.
Third, moving to the potential medical applications, we still
need to learn muchmore about iPSCs before we can confidently
abandon all other research pathways aimed at obtaining plurip-
otent cells. The reason is that we still need to determine, through
the contribution of a large enough number of laboratories
working on a wide enough array of cell types and disease
targets, the extent to which iPSCs are able to generate in vitro,
in a predictable and robust manner, differentiated cell types
that are then integrated into living tissues. The preliminary
evidence gives ample reason to hope this will be the case. Yet
what we call iPSCs represent the stochastic result of an epige-
netic adaptation, selected in culture on the basis of a variety of
assays. Of these, the main one is the ability to generate chimeric
mice and contribute to their germline. Even in this stringent
assay, the cells are actually asked to operate in the physiologic
context of normal cells from the host embryo, and we simply
do not know how much iPSCs are ‘‘aided’’ through additional
reprogramming cues in vivo, and how much this aid contributes
to the final outcome that we assay for. This potential second
layer of reprogramming would clearly be very different in the
human setting, since in many applications human iPSCs would
be expected to rely primarily on in vitro cues without the help
of surrounding developing tissue. Could it be that the way in
which the epigenome is reset in iPSCsmakes thembetter suited,
in vitro, for differentiating into certain cell types than others?
Could it be that, for the way in which reprogramming is achieved,
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derived ESCs—for certain applications? We simply do not
know. It bears mentioning that, by using tetraploid complemen-
tation in the mouse, iPSCs have been used to generate midges-
tation mice (Wernig et al., 2007); however, no group has yet
shown that iPSCs can generate live-born pups, in contrast to
work with ESCs. It is surely a simple exercise of caution not to
abandon at this stage other avenues of research, even when,
as in the case of iSCNT, they appear from the outset more diffi-
cult and less likely to succeed (Hyun et al., 2007b). The trajectory
of science has surprised us before.
Thus, we believe that iSCNT research remains a valuable
option to be considered and evaluated in any research trajectory
that strives for the eventual clinical translation of human stem
cells and the development of stem cell-based therapies. That
is, if one accepts that the clinical translation of human stem cells
and their direct derivatives is of social or humanitarian impor-
tance—in fact of compelling importance in the ethical justifica-
tions of stem cell research in some traditions—then one has
a very strong presumptive reason to allow iSCNT embryos to
be created for the advancement of basic research where
proposals meet criteria (c), (d), and (e) above.
Ethical Factors
Although hESCs could theoretically be obtained by the process
of hSCNT, the process requires the use of donated human eggs,
which are in short supply. Some commentators have expressed
ethical concerns about the possibility of undue inducement
and exploitation of women that arise from questions about
compensation for egg donation (Check, 2006). Insofar as this
ethical controversy remains unsettled, the successful use of
animal eggs could provide the benefit of reducing the need
for human egg donors in research. If scientists are able to trans-
fer human genetic material into enucleated animal eggs to
produce human stem cells, many more stem cells will be avail-
able for research. This ethical point favors iSCNT research.
One commentator has expressed the worry that successes in
iSCNT research will lead to the widespread exploitation of egg
donors pressured by researchers to provide human oocytes to
fuel a subsequent increased interest in hSCNT studies (Baylis,
2008). We, along with several other bioethicists, do not believe
this slippery-slope argument actually supports the conclusion
that iSCNT research is unethical in its own right (Nelson, 2008;
Savulescu and Skene, 2008). While we agree that potential
exploitation of oocyte donors is a serious issue, we maintain
that the best course would be to deal with the threat of exploita-
tion squarely by scrutinizing and eliminating recruitment prac-
tices that unduly induce women to participate in research, rather
than through an unproven and unnecessarily stringent strategy
of banning all iSCNT research.
Most other ethical concerns about iSCNT embryos are no
different than the ethical concerns addressed in the Chimera
Report. Specifically, we adhere to the answers expressed in
that report concerning themixing of species as unnatural, a viola-
tion of taboos, and a violation of human dignity. One additional
concern with iSCNT embryos is that they generate cells with
a new genetic composition that includes also human genetic
material. Insofar as this fact raises animal welfare or human
dignity arguments, we have dealt with those arguments in theChimera Report. What is different about iSCNT embryos is that
they contain not a mixture of genetically different cells but a
mixture of genetic material within the same cell. An iSCNT
embryo is composed almost entirely of human DNA, but the
embryos (and stem cells derived from them) contain a very small
amount of mitochondrial DNA from the animal egg. If argued that
the level of human DNA makes iSCNT embryos, in effect, fully
human, we believe the answers lie in the arguments in support
of hSCNT and hESC research itself. Moral status issues have
already been debated in the context of research on IVF-gener-
ated human embryos and also those created by hSCNT for
research. Those embryos contain entirely human genetic mate-
rial, and yet it has been recognized that they can be ethically
created and used in research under strict ethical and regulatory
controls (ISSCR, 2006). Notably, in accordance with the ISSCR
Guidelines for the Conduct of Human Embryonic Stem Cell
Research (ISSCR, 2006), resultant embryos would not be culti-
vated for more than 14 days and not transferred to a uterus for
further development. Thus, we do not believe that the creation
and destruction of iSCNT embryos for research raise special
moral status concerns that exceed the concerns already placed
on human embryo use for stem cell science.
Conclusions
(1) The creation of human-animal iSCNT embryos for
research is ethically justifiable by the reasons set out in
our Chimera Report (conditions [a]–[e] above).
(2) As with chimera research, the creation of iSCNT embryos
for research should not be prohibited on the grounds that
it crosses the human/animal species boundary per se, nor
because it may be thought to violate human dignity.
Critiques of such arguments included in our chimera
report have equal force with regard to the creation of
iSCNT embryos.
(3) Special additional reasons justify the creation of iSCNT
embryos for research.
(4) The creation of iSCNT embryos for research is consistent
with our previous recommendations regarding chimeras,
and as various regulatory, oversight, and funding bodies
consider whether iSCNT should be permitted or included
in their portfolio, we encourage them to allow this
research to move forward.
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